BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 28122978)

  • 1. Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production.
    Zheng W; Ling L; Li Z; Wang H; Rui Y; Gao W; Wang S; Su X; Wei W; Yu XF
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28122978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins.
    Zhang W; Wang H; Li Z; Liu X; Liu G; Harris RS; Yu XF
    J Virol; 2014 Nov; 88(21):12528-40. PubMed ID: 25142583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55(GAG)) of the virion nucleocapsid proteins.
    Syed F; McCrae MA
    Arch Virol; 2009; 154(11):1797-805. PubMed ID: 19826902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolutionarily conserved requirement for core binding factor beta in the assembly of the human immunodeficiency virus/simian immunodeficiency virus Vif-cullin 5-RING E3 ubiquitin ligase.
    Han X; Liang W; Hua D; Zhou X; Du J; Evans SL; Gao Q; Wang H; Viqueira R; Wei W; Zhang W; Yu XF
    J Virol; 2014 Mar; 88(6):3320-8. PubMed ID: 24390335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins.
    Zhang J; Wu J; Wang W; Wu H; Yu B; Wang J; Lv M; Wang X; Zhang H; Kong W; Yu X
    Retrovirology; 2014 Sep; 11():77. PubMed ID: 25213124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
    Yoshikawa R; Izumi T; Yamada E; Nakano Y; Misawa N; Ren F; Carpenter MA; Ikeda T; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
    J Virol; 2016 Jan; 90(1):474-85. PubMed ID: 26491161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
    Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core-binding factor subunit beta is not required for non-primate lentiviral Vif-mediated APOBEC3 degradation.
    Ai Y; Zhu D; Wang C; Su C; Ma J; Ma J; Wang X
    J Virol; 2014 Oct; 88(20):12112-22. PubMed ID: 25122780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
    J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
    Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
    J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression.
    Zhou X; Han X; Zhao K; Du J; Evans SL; Wang H; Li P; Zheng W; Rui Y; Kang J; Yu XF
    J Virol; 2014 Mar; 88(5):2555-63. PubMed ID: 24352440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
    Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
    J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
    Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
    PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor.
    Bachand F; Yao XJ; Hrimech M; Rougeau N; Cohen EA
    J Biol Chem; 1999 Mar; 274(13):9083-91. PubMed ID: 10085158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
    Ooms M; Letko M; Simon V
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
    Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
    Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological characterization of the gag gene products of bovine immunodeficiency virus.
    Battles JK; Hu MY; Rasmussen L; Tobin GJ; Gonda MA
    J Virol; 1992 Dec; 66(12):6868-77. PubMed ID: 1331499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.